Literature DB >> 13082423

Diagnosis and treatment of gouty arthritis.

J H TALBOTT.   

Abstract

The characteristic phenomena of acute gouty arthritis are acute arthritis in a middle-aged male, associated with serum uric acid above 6 mg. per 100 cc. and a satisfactory response to colchicine. Roentgenographically observable changes do not occur early. In recent years uric acid metabolism has been studied by means of isotope techniques utilizing labeled substances. Uric acid is excreted in relatively constant amounts by humans and is little affected by variations in dietary intake, except for purine or nucleic acid substances. Persons with gout have a greater total amount of uric acid and a lower turnover than normal persons. In the treatment of acute attacks of gout colchicine is still the most practical single drug, even though its pharmacologic action remains unknown. Benemid (probenecid) is a powerful uricosuric agent of low toxicity which has been subjected to extensive clinical trial for three years. It causes inhibition of the resorption of urate from the glomerular filtrate; the site of action is believed to be the tubular cells. The author's usual dose is 2 gm. a day. This has caused a lowering of the uric acid in the serum and an increase in the urinary output.

Entities:  

Keywords:  GOUT; PROBENECID/therapeutic use

Mesh:

Substances:

Year:  1953        PMID: 13082423      PMCID: PMC1521848     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  8 in total

1.  Current principles of management in gout.

Authors:  A B GUTMAN; T F YU
Journal:  Am J Med       Date:  1952-12       Impact factor: 4.965

2.  A factorial experiment to test the effect of various types of diets on uric acid excretion of normal human subjects.

Authors:  D WILSON; C BISHOP; J H TALBOTT
Journal:  J Appl Physiol       Date:  1952-01       Impact factor: 3.531

3.  The effect of benemid (P-[DI-N-propylsulfamyl]-benzoic acid) on uric acid metabolism in one normal and one gouty subject.

Authors:  C BISHOP; R RAND; J H TALBOTT
Journal:  J Clin Invest       Date:  1951-08       Impact factor: 14.808

4.  Pool size, turnover rate, and rapidity of equilibration of injected isotopic uric acid in normal and pathological subjects.

Authors:  C BISHOP; W GARNER; J H TALBOTT
Journal:  J Clin Invest       Date:  1951-08       Impact factor: 14.808

5.  The role of gout in the formation of urinary calculi.

Authors:  W E KITTREDGE; R DOWNS
Journal:  J Urol       Date:  1952-06       Impact factor: 7.450

6.  The effect of salicylates and adrenocorticotropic hormone upon the miscible pool of uric acid in gout.

Authors:  J D BENEDICT; P H FORSHAM; M ROCHE; S SOLOWAY; D STETTEN
Journal:  J Clin Invest       Date:  1950-08       Impact factor: 14.808

7.  Phenylbutazone (butazolidin) in rheumatoid arthritis and gout.

Authors:  W C KUZELL; R W SCHAFFARZICK; B BROWN; E A MANKLE
Journal:  J Am Med Assoc       Date:  1952-06-21

8.  Therapeutic value of probenecid (benemid) in gout.

Authors:  L R PASCALE; A DUBIN; W S HOFFMAN
Journal:  J Am Med Assoc       Date:  1952-07-26
  8 in total
  2 in total

1.  Recent advances in rheumatic diseases.

Authors:  E W BOLAND
Journal:  Calif Med       Date:  1955-02

2.  Probenecid Application Prevents Clinical Symptoms and Inflammation in Experimental Autoimmune Encephalomyelitis.

Authors:  Nadine Hainz; Sandra Wolf; Thomas Tschernig; Carola Meier
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.